MANAC Chemical Partners Co.,Ltd. (4360) Stock Price

Manac Chemical Partners manufactures and sells chemical products. The company specializes in bromine compounds and operates a diverse product portfolio with small-batch, high-variety production. Its products serve multiple industries including flame retardants, pharmaceuticals, reagents, IT materials, and industrial chemicals.

The company holds Manac Inc. and its 100% subsidiary Manac (Shanghai) Trading Co., Ltd. as consolidated subsidiaries, providing management guidance to Manac Inc. Manac (Shanghai) Trading Co., Ltd. handles the import and export of chemical products within China.

MC Service Inc. operates as a non-consolidated equity method non-applicable subsidiary, providing services such as warehouse leasing to Manac Inc. Iodine Fine Chem Inc. serves as an equity method non-applicable affiliate, developing, manufacturing, and selling iodine-related products.

Manac Chemical Partners operates three business segments: Fine Chemicals, Flame Retardants, and Health Support. The Fine Chemicals segment provides functional materials used in pharmaceuticals and high-tech applications. The Flame Retardants segment supplies products for electrical appliances and automotive components. The Health Support segment provides raw materials for hemodialysis pharmaceuticals and antimicrobial agents.

Manac Chemical Partners aims to provide value not only to the pharmaceutical and advanced technology sectors, but to society as a whole, through the creation of chemistry-based technologies and products. The company actively pursues collaboration with diverse partners, combining knowledge and expertise to contribute to the realization of a sustainable society.

The company regards return on equity (ROE) as a key management indicator. In its medium-term plan announced in June 2024, the company has set an ROE target of 8% or higher. To achieve this goal, the company is advancing management focused on operational efficiency of invested capital and profitability.

Manac Chemical Partners leverages its strengths in bromination and iodination technologies to pursue new technology development and market expansion. Under its medium-term plan for fiscal years 2024-2027, the company will progressively advance business restructuring and expansion, implementing growth investments to enhance corporate value.

The company's operating environment shows the fine chemicals business progressing steadily due to market recovery in the semiconductor sector, while the flame retardant business faces deteriorating profitability due to weak domestic and overseas demand and intensifying competition. In response, the company has prioritized revenue recovery, implementing price reviews and business portfolio restructuring.

In the fine chemicals business, the company is focusing on creating high-performance, high-value-added products to improve profitability of existing products and acquire new projects. The company is pursuing growth through expanded contract manufacturing of semiconductor-related products, with ongoing investments at the Fukuyama plant.

In the flame retardant business, the company is urgently addressing profitability improvements through price revisions and optimization of manufacturing processes. The company is also intensifying efforts to accelerate revenue generation from new product development.

In the health support business, the company maintains supply chain stability, providing stable supply of artificial dialysis raw materials and antimicrobial agent raw materials. Through this, the company aims to continuously provide products needed by society.

Furthermore, the company recognizes its corporate social responsibility and is strengthening internal controls and ensuring thorough compliance. The company prioritizes securing and developing excellent talent, safe operations, and environmental considerations, continuing measures to minimize business risks.